Mesoblast Limited (MSB.AX)
| Previous close | 1.1500 |
| Open | 1.1500 |
| Bid | 1.1250 x 0 |
| Ask | 1.1300 x 0 |
| Day's range | 1.1100 - 1.1600 |
| 52-week range | 0.2550 - 1.3300 |
| Volume | |
| Avg. volume | 8,467,087 |
| Market cap | 1.284B |
| Beta (5Y monthly) | 2.45 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1400 |
| Earnings date | 29 July 2024 - 02 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.73 |
GlobeNewswireFDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
If Approved, RYONCIL will be the First Allogeneic “Off-the-Shelf” Cellular Medicine in the US, and the First Cell Therapy for Children Up To 18 Years Old with SR-aGVHDNEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for Ryoncil® (remestemcel-L) in the tre
- GlobeNewswire
Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product rexlemestrocel-L in patients with chronic low back pain (CLBP) due to inflammatory degenerative disc disease of less than five years duration has commenced enrollment at multiple sites across the United
Simply Wall St.July 2024 ASX Leaders With High Insider Ownership And Strong Growth Prospects
As the Australian market experiences a positive uptick, with the ASX200 poised to climb over one percent this morning following robust gains on Wall Street, investors are keenly observing trends and opportunities. In such an environment, growth companies with high insider ownership can be particularly appealing, as they often signal strong confidence from those closest to the company's operations and future.
